Edition:
United States

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

5.16USD
21 Feb 2018
Change (% chg)

$-0.22 (-4.09%)
Prev Close
$5.38
Open
$5.40
Day's High
$5.50
Day's Low
$5.15
Volume
130,528
Avg. Vol
79,477
52-wk High
$9.40
52-wk Low
$3.88

Chart for

About

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active... (more)

Overall

Beta: 1.28
Market Cap(Mil.): $161.43
Shares Outstanding(Mil.): 30.01
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 187.16 16.73
EPS (TTM): -- -- --
ROI: -- -0.71 35.60
ROE: -- -3.52 17.23

BRIEF-Conatus Pharmaceuticals reports Q3 revenue of $9.6 million

* Conatus Pharmaceuticals Inc reports third quarter 2017 financial results and program updates

Nov 01 2017

BRIEF-EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC

* EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC

Oct 18 2017

Competitors

  Price Chg
BASF SE (BASFn.DE) €87.49 +0.01
Johnson & Johnson (JNJ.N) $129.91 -0.96
Novartis AG (NOVN.S) CHF80.20 -0.26
Merck & Co., Inc. (MRK.N) $54.55 -0.43
Roche Holding Ltd. (ROG.S) CHF223.50 -0.40
Roche Holding Ltd. (RO.S) CHF227.60 +0.80

Earnings vs. Estimates